Multiple Myeloma of the Thyroid Cartilage

A 60-year-old male presented with hoarseness. His past medical history was remarkable for a plasmacytoma of the left maxillary sinus having been resected without systemic evidence of plasma cell myeloma (PCM), also known as multiple myeloma (MM), at the time. This maxillary sinus disease recurred and was treated with radiation. Workup for PCM was conducted. Treatment included melphalan and autologous stem cell transplant. Because of the therapeutic and prognostic implications, a Plasma cell neoplasm (PCN) in a neck mass must be carefully evaluated by clinical and pathological criteria in order to distinguish plasmacytoma from PCM. PCN involvement of the thyroid cartilage is very rare, with only 5 previously reported cases.

Download Full-text

Prognostic Implications of a Rising Serum Monoclonal Protein and Free Light Chains post Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Transplantation and Cellular Therapy ◽

10.1016/j.jtct.2020.11.022 ◽

2020 ◽

Author(s):

Harsh Parmar ◽

Abdullah S. Al Saleh ◽

Alissa Visram ◽

Rahma Warsame ◽

Taxiarchis Kourelis ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Stem Cell Transplant ◽

Autologous Stem Cell Transplant ◽

Light Chains ◽

Cell Transplant ◽

Free Light Chains ◽

Monoclonal Protein ◽

Prognostic Implications

Download Full-text

Extramedullary Plasmacytoma in the Maxillary Sinus

Philippine Journal of Otolaryngology Head and Neck Surgery ◽

10.32412/pjohns.v24i2.683 ◽

2009 ◽

Vol 24 (2) ◽

pp. 27-31

Author(s):

Jennifer De Silva-Leonardo ◽

Rosario R. Bito-Ricalde ◽

Jose Roberto V. Claridad ◽

Erasmo Gonzalo DV. Llanes

Keyword(s):

Multiple Myeloma ◽

Maxillary Sinus ◽

Plasma Cell ◽

Systemic Disease ◽

Signs And Symptoms ◽

Final Diagnosis ◽

Extramedullary Plasmacytoma ◽

Complete Excision ◽

Left Maxillary Sinus ◽

High Index Of Suspicion

Objective: To describe an intranasal mass initially diagnosed and treated as benign, that eventually turned out to be a malignant extramedullary plasmacytoma of the maxillary sinus, and to review the literature on its presenting signs and symptoms, diagnosis, management and pathophysiology. Methods: Design: Case Report Setting: Tertiary Public Hospital Patient: One Results: A 45-year-old male with persistent nasal obstruction and intermittent epistaxis underwent several biopsies of a mass shown on computed tomography scans as heterogeneously enhancing, expansile, occupying the left maxillary sinus with extension into the left nasal cavity with areas of erosion. Immunohistochemical staining was negative for cytokeratin (CK) and leukocyte common antigen (LCA). Complete excision yielded a final histopathologic interpretation of plasmacytoma. Laboratory examinations excluded multiple myeloma. The final diagnosis was extramedullary plasmacytoma and he was treated with post-operative adjuvant radiotherapy. Conclusion: Plasmacytoma may present in the sinu-nasal region and be part of a systemic disease like multiple myeloma. A high index of suspicion and thorough initial histopathological work-up may help in establishing a definitive diagnosis and providing optimum treatment. Keywords: Plasmacytoma, plasma cell tumor, multiple myeloma, plasma cell myeloma, extramedullary plasmacytoma

Download Full-text

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Case Medical Research ◽

10.31525/ct1-nct03901963 ◽

2019 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Minimal Residual Disease ◽

Maintenance Treatment ◽

Stem Cell Transplant ◽

Residual Disease ◽

Autologous Stem Cell Transplant ◽

Cell Transplant ◽

Newly Diagnosed ◽

Minimal Residual

Download Full-text

Patient‐reported outcomes following autologous stem cell transplant for patients with multiple myeloma

eJHaem ◽

10.1002/jha2.231 ◽

2021 ◽

Author(s):

Noa Biran ◽

Wanting Zhai ◽

Roxanne E. Jensen ◽

Jeanne Mandelblatt ◽

Susan Kumka ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Patient Reported Outcomes ◽

Stem Cell Transplant ◽

Autologous Stem Cell Transplant ◽

Cell Transplant ◽

Patient Reported

Download Full-text

Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma

Cancers ◽

10.3390/cancers13020256 ◽

2021 ◽

Vol 13 (2) ◽

pp. 256

Author(s):

Ichiro Hanamura

Keyword(s):

Multiple Myeloma ◽

Hematological Malignancy ◽

Treatment Approach ◽

Current Knowledge ◽

Chromosome 1 ◽

Plasma Cell Neoplasm ◽

Chromosome Arm ◽

Cell Neoplasm ◽

Prognostic Implications ◽

Tandem Duplications

Multiple myeloma (MM), a plasma cell neoplasm, is an incurable hematological malignancy characterized by complex genetic and prognostic heterogeneity. Gain or amplification of chromosome arm 1q21 (1q21+) is the most frequent adverse chromosomal aberration in MM, occurring in 40% of patients at diagnosis. It occurs in a subclone of the tumor as a secondary genomic event and is more amplified as the tumor progresses and a risk factor for the progression from smoldering multiple myeloma to MM. It can be divided into either 1q21 gain (3 copies) or 1q21 amplification (≥4 copies), and it has been suggested that the prognosis is worse in cases of amplification than gain. Trisomy of chromosome 1, jumping whole-arm translocations of chromosome1q, and tandem duplications lead to 1q21+ suggesting that its occurrence is not consistent at the genomic level. Many studies have reported that genes associated with the malignant phenotype of MM are situated on the 1q21 amplicon, including CKS1B, PSMD4, MCL1, ANP32E, and others. In this paper, we review the current knowledge regarding the clinical features, prognostic implications, and the speculated pathology of 1q21+ in MM, which can provide clues for an effective treatment approach to MM patients with 1q21+.

Download Full-text